“The medical device sector faces some serious challenges in the coming year,and we look forward to his leadership and counsel.” The Massachusetts Medical Device Industry Council (MassMEDIC) was establishedin 1996 by medical device company executives interested in promoting theunique interests of the Bay State’s vibrant medical technology sector. Theorganization has grown to over 300 members, primarily manufacturers, productdevelopers, suppliers, research institutions and academic health centers. “I am very honored and excited to support MassMEDIC and our member companies.This is one of the premier medical device trade organizations in North Americaand it provides a significant resource to many regional manufactures andsuppliers,” Taylor stated.”MassMEDIC has a long history of being very activeon government affairs affecting our industry at the federal and state level.The organization also hosts a wide variety of networking events and provides awide range of free publications to our members. RALEIGH, N.C., July 14, 2009 (GLOBE NEWSWIRE) — Capital Bank Corporation(Nasdaq:CBKN) will host a conference call on Wednesday, July 22, 2009 beginningat 11:00 a.m Eastern Daylight Time. The purpose of the call will be to provideinterested parties with financial information regarding the quarter ended June30, 2009. The Company plans to release financial results for the quarter endedJune 30, 2009 on Tuesday, July 21, 2009.For those without access to the Internet, the conference call can be accessed bycalling 1-800-895-0231, meeting ID: CBKN. The company’s website is provided during this webcast contains forward-looking statements.These statements involve risks and uncertainties that could cause actual resultsto differ materially.

Factors that could cause actual results to differmaterially are discussed in Capital Bank Corporation’s filings with theSecurities and Exchange Commission, including its Annual Report on Form 10-K,its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K. Pleaserefer to the Securities and Exchange Commission’s website at whereyou can review those documents. Capital Bank Corporation does not undertake aduty to update any forward-looking statements made during this webcast.Shortly after the conclusion of this webcast, a replay will be made available atCapital Bank Corporation’s website at Please rememberthat this discussion is current only at the time of the live call, and replaylisteners should refer to Capital Bank Corporation’s press releases andSecurities and Exchange Commission filings for updates.-0-CONTACT: Capital Bank Corporation B. Grant Yarber, President and Chief Executive Officer 919-645-3494 . (To read other Reuters “Buy or Sell” items, pleasedouble-click on [BUYSELL/]) * Bulls see attractive valuation, healthy pipeline * Bears cite product recalls, share erosion in key markets By Susan Kelly CHICAGO, July 14 (Reuters) – Shares of medical technologybellwether Medtronic Inc (MDT.N) have shed 40 percent of theirvalue from a year ago and now trade at a discount to peers inthe device sector. The Minneapolis-based pacemaker pioneer and world’s largeststand-alone maker of medical devices has a promising pipelinedestined to enhance its stable of proven products to treatprevalent ailments ranging from heart disease and diabetes toneurological disorders and back pain.

Yet Medtronic’s shares rate a “buy” or “outperform” ratingfrom just half of the Wall Street analysts who follow thecompany, according to Reuters Estimates. What’s not to like? DOGGED BY QUALITY ISSUES “They have a great pipeline and look attractive from avaluation point of view, and they keep stubbing their toe everytime they turn around,” said Tim Nelson, healthcare analystwith First American Funds, which holds a small position inMedtronic. He ticks off a list of woes: last week’s recall of infusionsets for Medtronic’s Paradigm insulin pumps, the recent federalsubpoenas related to a former U.S. Army surgeon accused offabricating study data on the company’s Infuse bone proteinproduct, the continued overhang from a 2007 recall of itsFidelis brand of leads for connecting implantabledefibrillators to the heart. “You just shake your head — there they go again,” saidNelson, who does not currently recommend buying the stock.”It’s hard to get excited when you have quality concernsfloating around.” MARKET SHARE EROSION Analysts point to a second persistent concern giving pauseto would-be Medtronic bulls: Rivals are chipping away at thecompany’s dominant position in both the spine products andheart rhythm device markets.